Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

Haematologica. 2022 Jul 1;107(7):1681-1686. doi: 10.3324/haematol.2021.279564.
No abstract available

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Brentuximab Vedotin
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease* / drug therapy
  • Humans
  • Immunoconjugates* / therapeutic use
  • Salvage Therapy
  • Stem Cell Transplantation
  • Transplantation, Autologous


  • Immunoconjugates
  • Brentuximab Vedotin

Grant support

Funding: Takeda France provided a grant to support the central PET review for this study.